AYJ Stock Chart & Stats
€2.78
-€0.06(-2.90%)
At close: 4:00 PM EDT
€2.78
-€0.06(-2.90%)
Day’s Range― - ―
52-Week Range€2.04 - €5.13
Previous CloseN/A
Volume52.05K
Average Volume (3M)11.52K
Market Cap
€477.72M
Enterprise Value€516.36M
Total Cash (Recent Filing)€121.53M
Total Debt (Recent Filing)€210.23M
Price to Earnings (P/E)―
Beta1.12
Next Earnings
Nov 12, 2026EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.90
Shares Outstanding189,771,240
10 Day Avg. Volume6,046
30 Day Avg. Volume11,515
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)5.89
Price to Sales (P/S)3.58
P/FCF Ratio-10.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.44
Revenue Forecast (FY)€151.44M
Bulls Say, Bears Say
Bulls Say
Late-stage Lyme Vaccine OpportunityThe Lyme program offers a potentially transformative growth opportunity because it is described as the only late-stage candidate and could become the first licensed Lyme vaccine in about 30 years. Positive efficacy, safety, and advancing regulatory review could materially expand Valneva’s future commercial platform if approval follows.
Restructuring Supports Cost ImprovementThe restructuring addresses the company’s cost base through workforce reductions and project prioritization rather than relying only on revenue growth. If executed as planned, the program should improve operating leverage, reduce cash consumption, and strengthen the commercial business’s ability to generate positive cash flow over coming quarters.
Operating Expense DisciplineLower R&D, marketing, distribution, and G&A spending demonstrates tangible expense discipline across several functions. Sustaining these reductions can preserve cash while management concentrates resources on higher-impact vaccines and markets, improving the company’s ability to support its portfolio during a period of weak revenue.
Bears Say
Deepening Losses And Margin PressureThe sharp widening of operating and adjusted EBITDA losses shows that current sales do not yet cover the company’s cost structure. Persistent losses reduce financial flexibility and make successful execution of restructuring and pipeline programs increasingly important to achieving sustainable profitability.
Declining Product And Total RevenueThe broad decline in total revenue and product sales indicates weaker commercial performance across the existing portfolio, not merely a single isolated product issue. Lower scale can reduce operating leverage and makes future growth more dependent on recovery in travel-related demand or successful new-product launches.
Persistent Cash Burn And LeverageOngoing negative operating and free cash flow means Valneva has not consistently funded operations internally, while the shrinking equity base has increased leverage. Continued cash burn could constrain investment in development and commercialization and increase reliance on future debt or equity funding.
Valneva News
AYJ FAQ
What was Valneva SE’s price range in the past 12 months?
Valneva SE lowest stock price was €2.04 and its highest was €5.13 in the past 12 months.
What is Valneva SE’s market cap?
Valneva SE’s market cap is €477.72M.
When is Valneva SE’s upcoming earnings report date?
Valneva SE’s upcoming earnings report date is Nov 12, 2026 which is in 24 days.
How were Valneva SE’s earnings last quarter?
Valneva SE released its earnings results on Aug 13, 2026. The company reported -€0.17 earnings per share for the quarter, missing the consensus estimate of -€0.089 by -€0.081.
Is Valneva SE overvalued?
According to Wall Street analysts Valneva SE’s price is currently Overvalued.
Does Valneva SE pay dividends?
Valneva SE does not currently pay dividends.
What is Valneva SE’s EPS estimate?
Valneva SE’s EPS estimate is -0.09.
How many shares outstanding does Valneva SE have?
Valneva SE has 189,771,240 shares outstanding.
What happened to Valneva SE’s price movement after its last earnings report?
Valneva SE reported an EPS of -€0.17 in its last earnings report, missing expectations of -€0.089. Following the earnings report the stock price went down -3.175%.
Which hedge fund is a major shareholder of Valneva SE?
Currently, no hedge funds are holding shares in DE:AYJ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Valneva SE
Valneva SE is a specialized biotechnology company focused on developing and bringing to market preventative vaccines for infectious diseases with significant unmet medical needs. Their commercial offerings for travelers include IXIARO, a vaccine against Japanese encephalitis, and DUKORAL, an oral vaccine designed to protect against diarrhea caused by Vibrio cholera and specific heat-labile toxin-producing Enterotoxigenic Escherichia coli. The company also progressed VLA2001, a vaccine candidate targeting SARS-CoV-2. In its development pipeline, Valneva has VLA15, a Lyme disease vaccine candidate that has concluded Phase II clinical trials, and VLA1553, a chikungunya virus vaccine candidate currently undergoing Phase III evaluation. The company distributes its products across the United States, Canada, various European nations including Germany, Austria, the Nordics, and the United Kingdom, as well as other global markets. Valneva SE has established strategic partnerships, notably with Pfizer, Inc. for the joint development and commercialization of its Lyme disease vaccine, and with Instituto Butantan for the creation, manufacturing, and marketing of a single-shot chikungunya vaccine. The company was established in 1998 and operates from its headquarters in Saint-Herblain, France.